OPNT005 is a novel heroin vaccine developed by the Walter Reed Army Institute of Research (WRAIR) in collaboration with the National Institute on Drug Abuse (NIDA), a division of the National Institute of Health (NIH). This heroin vaccine is designed to generate antibodies to heroin that circulate in the bloodstream. These antibodies bind to heroin injected into the bloodstream. The heroin bound to the antibody is too large to enter the brain. Keeping heroin out of the brain will block both its pleasurable and harmful effects. Because the antibodies generated by this vaccine are highly specific to heroin and its metabolites, it can be used in conjunction with other medications approved to treat OUDs, such as buprenorphine and methadone. Like other vaccines, the antibodies generated by an effective heroin vaccine can provide long-lasting “protection” against the effects of heroin.

Opiant has in-licensed a novel heroin vaccine developed by the Walter Reed Army Institute of Research (WRAIR) in collaboration with the National Institute on Drug Abuse (NIDA), a division of the National Institute of Health (NIH).

Disease Area

Opioid Use Disorder

PreclinicalPhase IPhase IIPhase IIINDAFDA Approval
Preclinical
Phase I
Phase II
Phase III
NDA
FDA Approval